These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 29558894)
1. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries. Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894 [TBL] [Abstract][Full Text] [Related]
2. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. Devine A; Harvey R; Min AM; Gilder MET; Paw MK; Kang J; Watts I; Hanboonkunupakarn B; Nosten F; McGready R BMC Infect Dis; 2017 Aug; 17(1):552. PubMed ID: 28793866 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510 [TBL] [Abstract][Full Text] [Related]
5. An economic analysis of premarriage prevention of hepatitis B transmission in Iran. Adibi P; Rezailashkajani M; Roshandel D; Behrouz N; Ansari S; Somi MH; Shahraz S; Zali MR BMC Infect Dis; 2004 Sep; 4():31. PubMed ID: 15347430 [TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Vimolket T; Poovorawan Y Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Ozawa S; Mirelman A; Stack ML; Walker DG; Levine OS Vaccine; 2012 Dec; 31(1):96-108. PubMed ID: 23142307 [TBL] [Abstract][Full Text] [Related]
8. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis. Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013]. Zhang SX; Sun PP; Xia Y Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719 [No Abstract] [Full Text] [Related]
10. The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review. Myran DT; Morton R; Biggs BA; Veldhuijzen I; Castelli F; Tran A; Staub LP; Agbata E; Rahman P; Pareek M; Noori T; Pottie K Int J Environ Res Public Health; 2018 Sep; 15(9):. PubMed ID: 30200406 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255 [TBL] [Abstract][Full Text] [Related]
12. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Leech AA; Kim DD; Cohen JT; Neumann PJ Value Health; 2018 Jul; 21(7):759-761. PubMed ID: 30005746 [TBL] [Abstract][Full Text] [Related]
13. Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022. Gharpure R; Chard AN; Cabrera Escobar M; Zhou W; Valleau MM; Yau TS; Bresee JS; Azziz-Baumgartner E; Pallas SW; Lafond KE PLoS Med; 2024 Jan; 21(1):e1004333. PubMed ID: 38181066 [TBL] [Abstract][Full Text] [Related]
14. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV. Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. Nayagam S; Sicuri E; Lemoine M; Easterbrook P; Conteh L; Hallett TB; Thursz M BMC Infect Dis; 2017 Nov; 17(Suppl 1):692. PubMed ID: 29143675 [TBL] [Abstract][Full Text] [Related]
16. Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential? Jazwa A; Coleman MS; Gazmararian J; Wingate LT; Maskery B; Mitchell T; Weinberg M Vaccine; 2015 Mar; 33(11):1393-9. PubMed ID: 25595868 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Fesenfeld M; Hutubessy R; Jit M Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973 [TBL] [Abstract][Full Text] [Related]
18. Targeted hepatitis E vaccination for women of childbearing age is cost-effective in China. Xia R; Sun S; Shen M; Zhang L; Zhuang G Vaccine; 2019 Sep; 37(39):5868-5876. PubMed ID: 31443991 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium. Tormans G; Van Damme P; Carrin G; Clara R; Eylenbosch W Soc Sci Med; 1993 Jul; 37(2):173-81. PubMed ID: 8351532 [TBL] [Abstract][Full Text] [Related]